Integrated analysis of randomized controlled trials evaluating bortezomib + lenalidomide + dexamethasone or bortezomib + thalidomide + dexamethasone induction in transplant-eligible newly diagnosed multiple myeloma

ObjectiveProviding the most efficacious frontline treatment for newly diagnosed multiple myeloma (NDMM) is critical for patient outcomes. No direct comparisons have been made between bortezomib + lenalidomide + dexamethasone (VRD) and bortezomib + thalidomide + dexamethasone (VTD) induction regimens...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Laura Rosiñol, Benjamin Hebraud, Albert Oriol, Anne-Laurène Colin, Rafael Ríos Tamayo, Cyrille Hulin, María Jesús Blanchard, Denis Caillot, Anna Sureda, Miguel Teodoro Hernández, Bertrand Arnulf, Maria-Victoria Mateos, Margaret Macro, Jesús San-Miguel, Karim Belhadj, Juan José Lahuerta, M. Brigid Garelik, Joan Bladé, Philippe Moreau
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Frontiers Media S.A. 2023-11-01
coleção:	Frontiers in Oncology
Assuntos:	multiple myeloma bortezomib lenalidomide dexamethasone thalidomide
Acesso em linha:	https://www.frontiersin.org/articles/10.3389/fonc.2023.1197340/full
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!